NCT03059446

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 167 (actual)
• Sponsor: Tobira Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203 \[NCT02217475\] or the AURORA study \[NCT03028740\].

Conditions

• Nonalcoholic Steatohepatitis
• Liver Cirrhosis
• Non-alcoholic Fatty Liver Disease

Interventions

Type	Name	Description
DRUG	Cenicriviroc	Cenicriviroc immediate release tablets

Timeline

• Start date: 2017-02-14
• Primary completion: 2021-01-05
• Completion: 2021-01-05
• First posted: 2017-02-23
• Last updated: 2022-02-02
• Results posted: 2022-02-02

Locations

71 sites across 11 countries: United States, Australia, Belgium, France, Germany, Hong Kong, Italy, Poland, Puerto Rico, Spain, United Kingdom

Regulatory

• FDA-regulated drug study